{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:12:42Z","timestamp":1789985562533,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jval.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T14:04:51Z","timestamp":1524578691000},"page":"1176-1185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population\u2013Based Observational Data"],"prefix":"10.1016","volume":"21","author":[{"given":"Han-I","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.03.007_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2009.08010.x","article-title":"The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research","volume":"148","author":"Smith","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jval.2018.03.007_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jval.2018.03.007_bib3","unstructured":"Haematological Malignancy Research Network. HMRN 2018. https:\/\/www.hmrn.org\/statistics\/incidence. [Accessed January 10, 2018]."},{"key":"10.1016\/j.jval.2018.03.007_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2018.03.007_bib5","first-page":"1422","article-title":"Cost analysis of common treatment options for indolent follicular non-Hodgkin\u2019s lymphoma","volume":"90","author":"van Agthoven","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2018.03.007_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.3109\/10428194.2011.592623","article-title":"Economic impact of disease progression in follicular non-Hodgkin lymphoma","volume":"52","author":"Beveridge","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2018.03.007_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6030","article-title":"Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin\u2019s lymphoma: a systematic review and economic evaluation","volume":"6","author":"Wake","year":"2002","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2018.03.007_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3816\/CLM.2008.n.020","article-title":"Cost-effectiveness of extended adjuvant rituximab for US patients aged 65\u201370 years with follicular lymphoma in second remission","volume":"8","author":"Hayslip","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jval.2018.03.007_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10428190701769665","article-title":"Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma","volume":"49","author":"Hornberger","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2018.03.007_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol Stockh Swed"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2018.03.007_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3310\/hta13suppl2-06","article-title":"Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin\u2019s lymphoma","volume":"13","author":"Boland","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2018.03.007_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3310\/hta13suppl1\/04","article-title":"Rituximab for the first-line treatment of stage III\u2013IV follicular lymphoma","volume":"13","author":"Dundar","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2018.03.007_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","article-title":"An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin\u2019s lymphoma in the UK","volume":"13","author":"Ray","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.03.007_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.03.007_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdq582","article-title":"Treatment of follicular non-Hodgkin\u2019s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up","volume":"22","author":"Soini","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jval.2018.03.007_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/11591540-000000000-00000","article-title":"Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic\/pharmacodynamic\/pharmacoeconomic analysis of rituximab for follicular lymphoma","volume":"30","author":"Pink","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.03.007_bib17","doi-asserted-by":"crossref","first-page":"978391","DOI":"10.1155\/2012\/978391","article-title":"Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare","volume":"2012","author":"Griffiths","year":"2012","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.jval.2018.03.007_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.12264","article-title":"Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study","volume":"92","author":"Blommestein","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2018.03.007_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3111\/13696998.2013.873044","article-title":"Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin\u2019s lymphoma in England and Wales","volume":"17","author":"Dewilde","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2018.03.007_bib20","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2018.03.007_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radio-immunotherapy consolidation versus observation following first-line therapy in follicular lymphoma patients","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.03.007_bib22","first-page":"17","article-title":"Cost-effectiveness analysis of rituximab maintenance treatment in patients with follicular lymphoma who respond to first line induction therapy in Portugal","volume":"8","author":"Carvalho","year":"2016","journal-title":"Rev Port Farmacoter"},{"key":"10.1016\/j.jval.2018.03.007_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10198-016-0775-4","article-title":"Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort","volume":"18","author":"Wang","year":"2017","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2018.03.007_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyy044","article-title":"Cohort Profile: The Haematological Malignancy Research Network (HMRN); a UK population-based patient cohort","author":"Smith","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jval.2018.03.007_bib25","series-title":"Haematology Cancer Clinical Guidelines","year":"2015"},{"key":"10.1016\/j.jval.2018.03.007_bib26","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jval.2018.03.007_bib27","unstructured":"NHS National Tariff Payment System 2016\/17. NHS England; 2016. Available from: https:\/\/www.gov.uk\/government\/publications\/nhs-national-tariff-payment-system-201617. [Accessed April 16, 2018]"},{"key":"10.1016\/j.jval.2018.03.007_bib28","series-title":"NHS reference costs 2015 to 2016","year":"2016"},{"key":"10.1016\/j.jval.2018.03.007_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0272989X13497998","article-title":"Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach","volume":"34","author":"Bagust","year":"2014","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2018.03.007_bib30","series-title":"Guide to the methods of technology appraisal 2013","year":"2013"},{"key":"10.1016\/j.jval.2018.03.007_bib31","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jval.2018.03.007_bib32","series-title":"Non-Hodgkin\u2019s lymphoma: diagnosis and management","year":"2016"},{"key":"10.1016\/j.jval.2018.03.007_bib33","series-title":"Rituximab for the first-line maintenance treatment of follicular non-Hodgkin\u2019s lymphoma","year":"2011"},{"key":"10.1016\/j.jval.2018.03.007_bib34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2018.03.007_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.03.007_bib36","series-title":"Programme Budgeting","year":"2013"},{"key":"10.1016\/j.jval.2018.03.007_bib37","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S2352-3026(17)30124-2","article-title":"Rituximab biosimilars: introduction into clinical practice","volume":"4","author":"Makita","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jval.2018.03.007_bib38","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3026(17)30127-8","article-title":"Biosimilars: an optimistic outlook, but vigilance is needed","volume":"4","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jval.2018.03.007_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11926-014-0447-2","article-title":"Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review","volume":"16","author":"Tosh","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jval.2018.03.007_bib40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1524-4733.2009.00678.x","article-title":"Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma","volume":"13","author":"van Gestel","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.03.007_bib41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12571","article-title":"A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model","volume":"96","author":"Blommestein","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2018.03.007_bib42","doi-asserted-by":"crossref","first-page":"e0177364","DOI":"10.1371\/journal.pone.0177364","article-title":"Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: a real-world cost-effectiveness analysis of sequential first- and second-line treatments","volume":"12","author":"De Groot","year":"2017","journal-title":"PLoS ONE"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151830278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151830278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T21:29:47Z","timestamp":1661030987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830151830278X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S109830151830278X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.03.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population\u2013Based Observational Data","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}